#United States #Salt Lake City #Kodiak Sciences #ABC Platform #eye treatment

Kodiak Sciences Showcases ABC Platform

Kodiak Sciences Inc., a leading biopharmaceutical company based in Palo Alto, California, made a significant impact at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting held from May 4 to 8 in Salt Lake City, Utah. The company presented seven significant scientific findings that underscore the versatility and power of its innovative ABC® (Antibody Biopolymer Conjugate) platform, which focuses on developing groundbreaking therapies for complex ocular diseases that have unmet medical needs.

Dr. Victor Perlroth, CEO of Kodiak Sciences, expressed enthusiasm about the recent data stemming from their ongoing research and development initiatives, stating, "This body of work further highlights the power and versatility of Kodiak’s ABC platform for the design and development of new medicines for complex multifactorial diseases with a high unmet need."

The presentations spanned various topics, primarily focusing on the application of Kodiak's bispecific protein platform, which is currently powering two novel research programs aimed at treating ocular inflammatory diseases and geographic atrophy. One particular highlight included the bispecific protein KSI-101, currently in clinical trials for treating macular edema secondary to inflammation (MESI).

The Poster Presentations:
1. Anti-inflammatory Bispecific Anti-TNF-α VHH Anti-IL-6 Antibody Fusion for the Treatment of Inflammatory Retinal Diseases: This research delves into the need for comprehensive treatment options that target the inflammatory pathways effectively.

2. Preserving Endothelial Barrier Function with Novel Bispecific Anti-Inflammatory Agents: The findings suggest that Kodiak’s novel anti-inflammatory agents have better outcomes compared to traditional monotherapies in preserving retinal vascular integrity.

3. Ocular Toxicity Study of KSI-101: The safety profile of KSI-101 was demonstrated in primate models, showcasing that the treatment was well-tolerated, thereby paving the way for further clinical development.

4. Systemic Review of Uveitic Macular Edema Outcomes: The poster revealed significant differences in uveitic macular edema presentations between adults and children, emphasizing the need for tailored therapeutic approaches for pediatric populations.

5. Development of Potent Bispecific Inhibitors for Geographic Atrophy: This work focuses on a combined therapeutic approach that targets both complement activation and cytokine signaling to tackle the progression of geographic atrophy, a severe form of age-related macular degeneration affecting a large population.

6. Delivery of Therapeutic Oligonucleotides via Antibody Biopolymer Conjugates: This innovative study demonstrated the ability of Kodiak’s platform to facilitate targeted drug delivery and effective gene modulation.

7. Effect of Polymer Architecture on Properties of Antibody Biopolymer Conjugates: This poster presents findings on how variations in polymer structure can optimize the properties of therapeutic candidates, thus enhancing their effectiveness.

About Kodiak Sciences

Kodiak Sciences, listed on the NASDAQ under the symbol KOD, is dedicated to transforming the treatment landscape for retinal diseases. Their pioneering ABC platform integrates sophisticated protein engineering and chemical approaches to create next-generation retinal therapeutics aimed at addressing the leading causes of blindness worldwide. Currently, Kodiak is advancing three clinical programs, with two being late-stage initiatives stemming from the ABC platform.

As the biopharmaceutical landscape continues to evolve, Kodiak Sciences remains at the forefront of innovation, aiming to develop medicines that can significantly alter the trajectory of ocular health. For further details, visit Kodiak Sciences.

Conclusion

With its recent presentations at ARVO 2025, Kodiak Sciences has reaffirmed its commitment to addressing critical needs in ocular healthcare through innovative research and development. Their diverse pipeline of therapies and the promising ABC platform stand to revolutionize the treatment of complex ocular diseases, making a marked difference in the lives of many patients.

• ---